
ADVANCE Phase III Study Results Published
Led by Professor Bi Nan and team, the world's first chemotherapy-free study in EGFR-mutant locally advanced NSCLC demonstrated that aumolertinib combined with radical radiotherapy extended median PFS from 7.4 to 34 months, reducing disease progression risk by 85%.
Cancer Hospital, Chinese Academy of Medical Sciences




